NL-OMON40306已完成不适用
Effect of Tocilizumab on subclinical arterial inflammation and stiffness in patients with active rheumatoid arthritis (DAS28 > 3.2) - tocilizumab and arterial stiffness in RA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients fulfilling the American College of Rheumatology criteria for RA at diagnosis
- •Active RA; DAS-28 score > 3.2
- •Indication for treatment with tocilizumab.
- •Female/male patients 18-80 years of age.
- •Mentally able to understand the written information and to make the decision to
- •participate.
- •Written Informed consent
排除标准
- •Pregnancy
- •Insulin dependent Diabetes Mellitus
- •Renal impairment (eGFR <30ml/min)
- •MI or sepsis in the past three months
- •Unable to lay flat for 30-45 minutes for the PWV measurement
研究者
相似试验
进行中（未招募）
1 期
Tociluzimab effect on Endothelial function in patients with Rheumatoid Arthritis - TEFRAPolyarthrite rhumatoïdeEUCTR2011-000215-79-FRCHU de Clermont Ferrand30
已完成
2 期
Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19COVID-19 disease.COVID-19, virus not identifiedU07.2IRCT20081027001411N4Tehran University of Medical Sciences40
已完成
3 期
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT00535782Hoffmann-La Roche132
招募中
3 期
Evaluation of The effect of tocilizumab on patients with severe Covid 19IRCT20210408050899N1Ahvaz University of Medical Sciences15
招募中
2 期
Evaluation of the Effects of Tocilizumab Administration in Hospitalized COVID-19 PatientsIRCT20151227025726N29Iran University of Medical Sciences50